Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I feel the same way..
In at the same price. They desperately need some kind of news.
Today is a good day to beef up those positions!
Here is one to look at: ETEV.ob
Let me know your thoughts on this one. It would be greatly appreciated.
Happy Friday!
Nice of you to open yesterday!
[video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show
Thursday August 21, 2:16 pm ET
VENICE, Fla., Aug. 21 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc. (OTC Bulletin Board: SFSH - News), a developer and marketer of innovative upper respiratory system therapies, today announced that the company's CEO, Charles Fust, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.
The interview gives viewers an overview of the company, and the significance of the company's latest press release.
To view the clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Charles-Fust-SFSH/215/902
SinoFresh®Nasal Spray Kills MRSA "Super-Bug" in Live Noses
Monday August 18, 11:59 am ET
SinoFresh®Passes First Key Test for Potential to Control "Super-Bug" MRSA
VENICE, FL--(MARKET WIRE)--Aug 18, 2008 -- SinoFresh HealthCare, Inc. (OTC BB:SFSH.OB - News) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh® nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh® nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.
The study showed that "SinoFresh® nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.
MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.
SinoFresh® nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh® Nasal Spray's mode of killing them is much lower," said Dr. Todhunter.
According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."
Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. (OTC BB:SFSH.OB - News) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh® Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh® products are available in major retail outlets nationwide. More information is available at www.sinofresh.com.
Conference Call Today
The conference call will take place at 10:30 a.m. eastern time. Interested parties should dial (866) 675-4790 or (913) 312-9330 (internationally) and reference passcode 9524581. There will be a playback available as well. To listen to the playback, please call (888) 203-1112 or (719) 457-0820 (internationally) and use the same passcode.
The conference call will also be webcast and will be available at http://sanconinc.com/web/ir.htm.
Immunosyn Corporation Files 10-Q
Thursday August 14, 11:23 am ET
LA JOLLA, Calif.--(BUSINESS WIRE)--Immunosyn Corporation (OTCBB: IMYN - News), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending June 30, 2008.
For the quarter ended June 30, 2008, the company incurred $629,884.00 in general and administrative expenses and $15,297.00 in interest expense which was funded from advances by affiliates of $26,527.00, accounts payable of $60,376.00, accrued expenses of ($1,498.00) and services rendered for stock of $529,250. As a result, the company had a Net Loss of $645,181.00 for the second quarter of 2008. During the same period in 2007, the company incurred $71,025.00 in general and administrative expenses, interest expense of $4,810.00 and had a Net Loss of $75,835.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.
“We have continued to significantly control costs this quarter and appreciated the advances from affiliates,” noted Stephen Ferrone, Immunosyn’s CEO. “In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC,” added Ferrone.
Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating diabetic ulcers. Immunosyn went public in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol “IMYN.”
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (OTCBB: IMYN - News) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company’s most recent public filings and Annual Report on Form 10-KSB for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
Contact:
The Blaine Group
Lisa Baker/Devon Blaine
310-360-1499
310-360-1498 (FAX)
blaine@blainegroupinc.com
I agree with Bobwins..
To avoid exposure and competition
Sancon signs Largest Computer Manufacturer in China
Largest Personal Computer Manufacturer in China Selects Sancon To Collect and Process Waste Packaging Materials From New Computer Deliveries and Installations in Country
Wednesday August 13, 9:48 am ET
Milestone Agreement Reflects Growing Trend in China to Become Environmentally Conscious
SHANGHAI, China--(BUSINESS WIRE)--Sancon Resources Recovery, Inc. (OTCBB:SRRY - News), a rapidly growing environmental services and waste recycling company, with operations in both China and Australia, announced today that it has entered into an agreement with China’s largest manufacturer of personal computers to collect and process all waste packaging materials resulting from the delivery and installation of computers at all of its corporate clients in China. Sancon will provide on-site collection of the materials, and recycle the waste packaging into reusable packaging materials. The computer maker will also share the profit from the sale of the recycled materials.
“We are excited to enter into this milestone agreement, under which we will work with one of the world’s largest and most prestigious manufacturers of computers to turn surplus packaging into reusable packaging materials,” said Jack Chen, Sancon’s Chief Executive Officer. “The opportunity in China is substantial, as sales of computers continue to grow at a double-digit annual rate. We believe this agreement reflects a trend, endorsed by the Chinese government, to become more environmentally responsible through recycling. We believe Sancon Resources Recovery is uniquely positioned to capitalize on these opportunities.”
About Sancon Resources Recovery Inc
Sancon Resources Recovery, Inc. is an environmental service and waste management company that operates recycling facilities in China and Australia. Sancon specializes in the collection and recovery of industrial and commercial solid wastes such as plastic, paper, cardboard, and glass. The recycled materials are re-used by Sancon's manufacturing customers in China to make a wide variety of new products including outdoor furniture, construction materials, building materials, road surface, and various new products. Sancon's China operation is licensed by the Chinese government for waste management services, and is certified with ISO 9001 and ISO14001 standards. For more information please visit: www.sanconinc.com.
Forward-looking statements:
The statements made in this press release, which are not historical facts, may contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.
Contact:
CEOcast, Inc. for Sancon Resources Recovery, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
or
Sancon Resources Recovery, Inc.
Jack Chen, +86 21 5284 3310 (CEO)
info@sanconinc.com
Happy Friday!
Nice open again. Like to see supporters out there!
I hope so!
Good to see many supporters out there. It's a great time to take a position here.
Nice open today.
Good trading.
The Small Business Company Delays Marketing Launch 30 Days
Friday August 1, 12:42 pm ET
SAN DIEGO--(BUSINESS WIRE)--The Small Business Company (OTCBB:SBCO - News), a provider of solutions for small businesses, announces it will begin its nationwide Direct Response TV ad campaign and new online marketing initiatives for the Company’s products starting in August 2008, a one month delay from previously announced plans. Cable channels where the Company’s 30-second ads will air include ESPN News, ESPN Classics, FX, Planet Green, Food Network, TLC, WE, Military and Speed.
“To handle the amount of traffic and sales we anticipate, it was prudent for us to take a step back to ensure we have a seamless integration and every piece fully tested and in place before we launch,” stated David Larson, the Company’s president. “This also provides our vendors additional time to ramp up for the quantities of CD packages and books we’ll require.”
About The Small Business Company
The Small Business Company markets products and services to small business owners enabling entrepreneurs to improve their existing business or start a small or home based business. Through the Company's coaching and products, small business owners, with limited time and resources, can focus and solve their most pressing problems quickly. For additional information on the Company, please visit www.TheSmallBizCo.com.
FORWARD-LOOKING SAFE HARBOR STATEMENT: To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties and the Company assumes no obligation to update any of the forward-looking statements in this release.
Contact:
The Small Business Company
David Larson, President
858-481-5617
dave@TheSmallBizCo.com
Nice open again today!
It's worth calling in your order.
I know it's time consuming but it's worth it.
Looking good today!
There is life out there :)
Thank you!
All of those who are distributors should have no reason not to become shareholders.
Think about it: If you are going to invest money to distribute product why not become a shareholder long term.
The keys to investing:
buy low (which is now), cash flow positive on your investment, pull out your inital investment, keep some long term if you believe in the company (which you do if you are a distributor)...Make Sense???
And who is going to take the time to do that?
I know its a paid however calling in limit orders will probably help.
It's worth calling to place an order
at these levels.
Can anyone find out why?
My point that I was making is that they can project revenues.
Trust me, I feel the same way.
That is way too much money..like I said in my previous post the CEO gets paid less annually.
This is where their money is going to:
http://www.ceocast.com/(tledxaynnirohk45g3xle3nb)/NewsLetters.aspx?id=459
I can't wait to see the commercials they put together.
Spreading the word out isn't that hard however they need some cash. Based on the charts money has been taken out of the stock. There has been negative money flow since April of this year.
I like the company but I think there is seller nickle and diming the stock.
IMYN turns into a Revenue Generating Bio-Tech Company
Versus Bio-Tech Developmental Company. (Think About It)
Significant things will happen now that the product is available in the U.S.
Great to hear your support!
Signs a contract worth $1.1 M
Leading Aerospace Firm Purchases Additional CASTion Designed Wastewater Treatment, Chemical Recovery System Totaling $1.1 Million
LITTLE ROCK, Ark., July 22 /PRNewswire-FirstCall/ -- ThermoEnergy Corporation's (OTC Bulletin Board: TMEN - News) CASTion subsidiary announced that a leading US aerospace and military supplier has purchased an additional CASTion custom-designed, proprietary chemical recovery and water conservation system to enhance the supplier's existing wastewater treatment process. The additional custom designed system is in keeping with the client's goal of minimizing its environmental impact on land, water, air, and human health through the beneficial reuse of water as well as recycling of primary manufacturing by-products. In total, the contract represents $1.1 million in revenue to ThermoEnergy's subsidiary.
"This contract is a strong example of the type of success our CASTion sales team is having in capitalizing on our robust 2008 pipeline," commented ThermoEnergy's CEO Dennis Cossey, "After spending the first two quarters focusing on building potential sales leads, we believe our pipeline is approaching $10M year to date and expect to close on a good portion of these sales in 2008. CASTion continues to prove itself as a market leader in industrial wastewater treatment and water conservation solutions, and we look forward to the rapidly improving ramp-up at CASTion, both from a revenue and profitability perspective."
The advanced wastewater treatment system being installed is one of the Company's CAST 2500 Systems; which will be coupled with a reverse osmosis unit and microfilter to treat various wastewaters produced during the manufacture of printed circuit boards. Virtually all the metals recovered from production rinse waters will either be reused or recycled. The new CAST 2500 unit will be an add-on to the initial reverse osmosis system purchased by the client in 2007.
About ThermoEnergy: ThermoEnergy is a diversified technologies company engaged in the worldwide commercialization of patented and/or proprietary municipal and industrial wastewater treatment and power generation technologies. The economic and environmental matrix of the Company's technologies represents a significant advancement in these key infrastructure industries. The Company currently has offices in Little Rock, AR, Worcester, MA, Hudson, MA, Jacksonville, FL, Baton Rouge, LA and New York, NY. Additional information on the Company and its technologies can be found on its website at www.thermoenergy.com.
ABOUT CASTion: CASTion is a fast growing developer and manufacturer of innovative wastewater treatment and recovery systems for industrial and municipal clients. Our systems are unique because they meet environmental regulations and provide a rapid rate of return on investment by recovering and reusing expensive feedstocks, reducing contaminated wastewater discharge and reusing wastewater in process operations. Our proprietary products CAST and RCAST are combined with off-the shelf technologies to provide systems that are inexpensive, easy to operate and reliable. Our wastewater treatment systems have application in aerospace, food processing, metal finishing, refineries, manufacturing and municipal wastewater. With recovery of feedstocks, avoidance of wastewater and contaminate discharge fees and the reuse of wastewater in your process our systems can deliver cost effective solutions to environmental problems. From our 20,000 square foot manufacturing facility in Worcester, Massachusetts we design, engineer, assemble and ship our systems worldwide. Additional information on the Company and its technologies can be found on its website at www.castion.com.
I completely agree with you.
Take Position Now!
Great prices..you know the stock will climb. Spread the word: The drug is available in the USA. :)
2008 Q2 Results
Tuesday July 22, 8:00 am ET
Quarterly Revenue Increases 73.3%, Gross Profit Rises 641% Leading to Diluted EPS of $0.02; Company Earns $0.06 for 2008 First Six Months
SHANGHAI, China--(BUSINESS WIRE)--Sancon Resources Recovery, Inc. (OTCBB:SRRY - News), a rapidly growing environmental services and industrial waste recycling company, with operations in both China and Australia, today announced record preliminary second quarter results for the period ended June 30, 2008.
The Company generated record 2008 second quarter revenue of approximately $2.93 million, a 73.3% increase compared to $1.69 million in the 2008 second quarter. Revenue increased due to strong growth in China. Gross profit increased 641% to $1.26 million compared to $0.17 million in the year earlier period. Gross profit declined from $1.51 million in the 2008 first quarter due to damage to roads and highways in certain cities the Company does business in as a result of the Wenchuan earthquake. This damage increased the amount of time it took to complete waste collections, increasing the cost to the Company. Many of the roads and highways have since been repaired.
Gross margin increased from 10.3% in the 2007 second quarter to 43% in the 2008 second quarter due to increased sales of higher margin services in China. 2008 second quarter net income was a record $0.37 million, or $0.02 per diluted share, compared to a loss of $(0.06) million or $0.00 per share in the year earlier period. The 2008 second quarter was the Company’s second consecutive quarter of profitability. 2008 first quarter net income was a record $0.79 million, or $0.04 per diluted share, compared to a loss of $(0.16) million, or $(0.01) per share in the year earlier period.
Despite the strong revenue growth in the 2008 second quarter, the Company’s revenue would have been even higher except for the disruption caused by the earthquake that impacted Sancon’s ability to offer environmental services in certain areas that were impacted by the earthquake. Profitability was also impacted by the Company’s decision to increase spending to develop ways to turn waste glass material into new usable products and materials, which it believes will allow it to generate additional sources of revenue and investments in additional infrastructure to support anticipated growth throughout the balance of 2008 and 2009.
“We are pleased to announce our second consecutive quarter of profitability,” said Jack Chen, Sancon’s Chief Executive Officer. “Despite challenges presented by the earthquake in China, which impacted our ability to offer services in certain markets, we continued to expand our customer base and market. The market in China is substantial and still in its early stages of growth, and we have positioned the Company to benefit from the Chinese government’s mandate to clean up the environment in the next 15 years. We will continue to strategically increase our recycling plants and depots to support growth in new Chinese cities and to expand the services we provide customers in our target markets.”
The Company expects to provide a business outlook for fiscal 2008 when it announces results in mid-August and will hold a conference call for the investment community to discuss its results. Details on the timing of the conference call will follow.
Are you willing to give a testimonial?
Two More Florida Cities Mandate Ethos FR(R) for All City Vehicles
Boca Raton, Bal Harbor Joining North Miami in Green Efforts
SAN DIEGO, CA--(MARKET WIRE)--Jun 25, 2008 -- Ethos Environmental, Inc. (OTC BB:ETEV.OB - News), a San Diego-based company, announced that two more south Florida municipalities have joined the City of North Miami in mandating the use of Ethos FR® in all city vehicles. In March of this year, the City of North Miami completed a testing protocol that resulted in a 12.5% improvement in fuel economy and a 19.34% reduction in harmful emissions with the use of Ethos Fuel Reformulator. Based on those results, North Miami mandated the use of Ethos FR® for the entire city fleet.
ADVERTISEMENT
Now, neighboring communities Bal Harbor and Boca Raton have completed their own testing periods. Bal Harbor Mayor Howard Berlin, along with the City Council, confirmed that the city's test vehicles showed a 12.6% improvement in fuel economy along with a reduction in harmful emissions -- as measured in opacity -- of 34%. Bal Harbor will be using Ethos FR® in all city vehicles, effective immediately.
In the nearby city of Boca Raton, a four-month testing period on municipal vehicles has also yielded excellent results. Boca Raton has authorized a purchase order to supply Ethos FR® for all city vehicles for one year.
Patrick Glennon, president of Ethos Environmental East, Inc., said, "We are very excited that these cities have seen the benefit of using Ethos FR®. This is an area of the country with high expectations for air quality and these cities have recognized that by using Ethos Fuel Reformulator they can bring immediate improvement to their environment and save on fuel budgets too. We commend the cities of Bal Harbor and Boca Raton for their extensive testing, and we look forward to continuing our service to them."
Ethos FR® is an ester-based fuel reformulating product that reduces harmful emissions while improving both fuel mileage and engine performance. Ethos FR®'s ability to integrate easily with existing fueling infrastructures makes it both an effective and realistic pro-environmental step that can be implemented by companies and municipalities of all sizes.
For additional information, please visit www.ethosfr.com.
Where did you buy the product?
It's huge!
They are so busy they need to stop and re group so they can get the news out. Wanted to post that just so its not too stagnant.
SRRY opened nice today.
July 5, 2008 - GREAT NEWS:
Source: www.osmondms.com
NOW you can see A Doctor for treatment with SF1019!
Argyll has been given permission to open the
Renewed Hope Clinic
95 North 400 East
PO Box 850
Beaver, Utah 84713
Phone: 435-438-5551
Fax: 888-587=9041
E-mail: SF1019@rehopeclinic.com
MITCHELL J. MELLING MD
They should be solid...
SRRY is paying out 8K per month for their services and a boat load of stock.
That's $96,000 a year...that's more than what the CEO makes a year.
The stock better become a $2 stock.
They did hire someone.
CEOcast, Inc. for Sancon Resources Recovery, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com